Basal subtype is predictive for response to cetuximab treatment in patient‐derived xenografts of squamous cell head and neck cancer
K Klinghammer, R Otto, JD Raguse… - … Journal of Cancer, 2017 - Wiley Online Library
Cetuximab is the single targeted therapy approved for the treatment of head and neck
cancer (HNSCC). Predictive biomarkers have not been established and patient stratification …
cancer (HNSCC). Predictive biomarkers have not been established and patient stratification …
[HTML][HTML] Characterization of 7A7, an anti-mouse EGFR monoclonal antibody proposed to be the mouse equivalent of cetuximab
Abstract The Epidermal Growth Factor Receptor (EGFR) is selectively expressed on the
surface of numerous tumours, such as non-small cell lung, ovarian, colorectal and head and …
surface of numerous tumours, such as non-small cell lung, ovarian, colorectal and head and …
Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer
SKA Blick, LJ Scott - Drugs, 2007 - Springer
Cetuximab (Erbitux®) is a human-mouse chimeric monoclonal antibody, which competitively
binds to the accessible extracellular domain of the epidermal growth factor receptor (EGFR) …
binds to the accessible extracellular domain of the epidermal growth factor receptor (EGFR) …
Inhibition of epithelial–mesenchymal transition by cetuximab via the EGFR‐GEP100‐Arf6‐AMAP1 pathway in head and neck cancer
Y Matsumoto, H Sakurai, Y Kogashiwa, T Kimura… - Head & …, 2017 - Wiley Online Library
Background Despite improved survival by the addition of a monoclonal antibody against
epidermal growth factor receptor (EGFR), cetuximab, to chemotherapy or radiotherapy for …
epidermal growth factor receptor (EGFR), cetuximab, to chemotherapy or radiotherapy for …
[HTML][HTML] A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and …
H Zhu, C Wang, J Wang, D Chen, J Deng… - Journal of Thoracic …, 2018 - ncbi.nlm.nih.gov
Background Epidermal growth factor receptor (EGFR) is reportedly overexpressed in most
esophageal tumors, but most targeted therapies showed no efficacy in non-selected …
esophageal tumors, but most targeted therapies showed no efficacy in non-selected …
[HTML][HTML] Phase I study of ficlatuzumab and cetuximab in cetuximab-resistant, recurrent/metastatic head and neck cancer
Cetuximab, an anti-EGFR monoclonal antibody (mAb), is approved for advanced head and
neck squamous cell carcinoma (HNSCC) but benefits a minority. An established tumor …
neck squamous cell carcinoma (HNSCC) but benefits a minority. An established tumor …
Treatment outcome under cetuximab-based therapy and individual ADCC capability in head and neck cancer
C Lo Nigro, L Lattanzio, D Vivenza, M Monteverde… - Cancer Research, 2016 - AACR
Abstract Introduction Cetuximab is a IgG1 monoclonal antibody against epidermal growth
factor receptor (EGFR) used for head and neck squamous cell carcinoma (HNSCC) …
factor receptor (EGFR) used for head and neck squamous cell carcinoma (HNSCC) …
[HTML][HTML] A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck …
EM Bahassi, YQ Li, TM Wise-Draper, L Deng… - European Journal of …, 2013 - Elsevier
BACKGROUND: Cetuximab is an epidermal growth factor receptor (EGFR)-blocking
antibody that has been approved for the treatment of patients with head and neck squamous …
antibody that has been approved for the treatment of patients with head and neck squamous …
Development and clinical indications of cetuximab
R Labianca, N La Verde… - The International journal …, 2007 - journals.sagepub.com
Cetuximab is a chimeric immunoglobulin G1 monoclonal antibody that targets the
extracellular domain of the epidermal growth factor receptor (EGFR) with high specificity and …
extracellular domain of the epidermal growth factor receptor (EGFR) with high specificity and …
Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells
Background: Nasopharyngeal carcinoma (NPC) is the most common head and neck cancer
in southern China and South East Asia. Epidermal growth factor receptor (EGFR) has been …
in southern China and South East Asia. Epidermal growth factor receptor (EGFR) has been …